ArQule, Inc. (ARQL) Insider Sells $6,674,584.90 in Stock

ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 2,301,581 shares of ArQule stock in a transaction on Wednesday, April 4th. The stock was sold at an average price of $2.90, for a total value of $6,674,584.90. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of NASDAQ ARQL opened at $2.85 on Monday. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.03. ArQule, Inc. has a 52 week low of $0.92 and a 52 week high of $3.35. The firm has a market capitalization of $248.26, a P/E ratio of -7.31 and a beta of 0.83.

How to Become a New Pot Stock Millionaire

ArQule (NASDAQ:ARQL) last issued its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.09). During the same period in the prior year, the firm posted ($0.10) earnings per share. equities analysts anticipate that ArQule, Inc. will post -0.31 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ARQL. Millennium Management LLC bought a new position in shares of ArQule in the fourth quarter worth $165,000. Northern Trust Corp increased its position in shares of ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 1,385 shares during the period. Virtu Financial LLC increased its position in shares of ArQule by 343.8% in the fourth quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 99,964 shares during the period. Deutsche Bank AG bought a new position in shares of ArQule in the fourth quarter worth $390,000. Finally, Point72 Asset Management L.P. bought a new position in ArQule in the third quarter valued at about $2,220,000. Institutional investors own 67.08% of the company’s stock.

A number of equities research analysts have recently weighed in on ARQL shares. Leerink Swann raised ArQule from a “market perform” rating to an “outperform” rating in a report on Thursday. Zacks Investment Research upgraded ArQule from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Tuesday, March 20th. Roth Capital initiated coverage on ArQule in a research report on Thursday, February 22nd. They issued a “buy” rating and a $5.00 price target on the stock. B. Riley set a $3.00 price target on ArQule and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, BidaskClub upgraded ArQule from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. ArQule currently has an average rating of “Buy” and an average target price of $4.08.

COPYRIGHT VIOLATION WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3342483/arqule-inc-arql-insider-sells-6674584-90-in-stock.html.

ArQule Company Profile

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Expect Approach Resources Inc.  Will Post Quarterly Sales of $29.21 Million
Brokerages Expect Approach Resources Inc. Will Post Quarterly Sales of $29.21 Million
Brokerages Anticipate Progressive Co.  Will Post Earnings of $0.84 Per Share
Brokerages Anticipate Progressive Co. Will Post Earnings of $0.84 Per Share
CPI Card Group  Receiving Somewhat Positive Press Coverage, Analysis Finds
CPI Card Group Receiving Somewhat Positive Press Coverage, Analysis Finds
Hugoton Royalty Trust  Getting Somewhat Positive Press Coverage, Analysis Shows
Hugoton Royalty Trust Getting Somewhat Positive Press Coverage, Analysis Shows
Pyxis Tankers  Receives News Sentiment Rating of 0.18
Pyxis Tankers Receives News Sentiment Rating of 0.18
TD Ameritrade  Shares Gap Down  After Earnings Miss
TD Ameritrade Shares Gap Down After Earnings Miss


© 2006-2018 Ticker Report. Google+.